Clinical pipeline Affimed focuses on innate immune engagement with ICE molecules across solid tumors and hematologic cancers, presenting multiple collaboration and co-development opportunities with NK cell therapies and PD-L1 inhibitors to expand combination strategies and accelerate clinical milestones.

Strategic partnerships Active exploration of AlloNK off-the-shelf NK cell therapies and industry collaborations via AB-101 and other partners suggests open avenues for BD discussions around monetization models, co-development, and access to complementary platforms.

Late-stage potential AFM24 exposure‑response data indicating higher drug exposure improves efficacy in NSCLC supports pursuing dose-optimization partnerships, strategic licensing, or co-development deals to maximize value with oncology-focused pharma.

Targeted expansion Lead candidates AFM13 AFM24 and AFM28 address CD30-positive lymphomas, EGFR-expressing solid tumors, and CD123 AML, offering a diversified portfolio for potential license deals, strategic investments, or regional commercialization rights.

Market indicators Recent regulatory and listing developments, including Nasdaq delisting considerations and solvency actions, signal a heightened need for strategic investors or buyers to support ongoing operations and accelerate clinical programs.